Targeted AgentsA Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Sponsor:

Alliance Foundation Trials, LLC.

Code:

NCT04486352

Conditions

Endometrial Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atezolizumab - 28 Day Cycle

Bevacizumab

Ipatasertib

Talazoparib

Trastuzumab emtansine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by Alliance Foundation Trials, LLC. on 2026-04-01.